lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
Lyophilized thymosin alpha 1 is typically stored refrigerated at 2 to 8 degrees Celsius and kept away from light. Reconstituted solutions are less stable and are usually used promptly after preparation. Repeated freeze-thaw cycles are avoided because they can promote aggregation and loss of activity. The peptide adsorbs to some plastic and glass surfaces, so a carrier protein is often added to dilute working solutions. Manufacturer instructions and published protocols both govern handling.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C129H215N33O55 | Calculated for the acetylated 28-residue peptide |
| Appearance | White to off-white powder | Lyophilized solid recovered from aqueous buffer |
| Solubility | Freely soluble in water | Typically dissolved in water or buffer before use |
| Typical storage | -20 C or below, desiccated | Protect from light and avoid repeated freeze-thaw cycles |
| Identity testing | Reverse-phase HPLC with mass spectrometry | Retention time and measured mass confirm the sequence |
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
According to the Centers for Disease Control and Prevention (CDC), average U.S. life expectancy at birth reached 79.0 years in 2024, its highest recorded level and an increase of 0.6 years over 2023. The CDC attributed the improvement mainly to lower mortality from unintentional injuries, COVID-19, heart disease, cancer, and homicide. Heart disease, cancer, and unintentional injuries remained the leading causes of death. In 2024, life expectancy at birth for American men rose to 76.5 years (+0.7 years compared to 2023), while life expectancy for women was 81.4 years (+0.3 years). Starting in 1998, life expectancy in the U.S. fell behind that of other wealthy industrialized countries, and Americans' "health disadvantage" gap has been increasing ever since. The Commonwealth Fund reported in 2020 that the U.S. had the highest suicide rate among the 11 high-income countries included in its study. Obesity affected 40.3% of U.S. adults aged 20 and older in August 2021–August 2023. The U.S. healthcare system far outspends that of any other country, measured both in per capita spending and as a percentage of GDP, but attains worse healthcare outcomes when compared to peer countries for reasons that are debated. The United States is the only developed country without a system of universal healthcare, and a significant proportion of the population that does not carry health insurance. Government-funded healthcare coverage for the poor (Medicaid) and for those age 65 and older (Medicare) is available to Americans who meet the programs' income or age qualifications.
==== Reduced probability of contamination ==== DMF-based workflows, particularly those using a closed configuration with a top-plate ground electrode, have been shown to be less susceptible to outside contamination compared to some conventional laboratory workflows. This can be attributed to minimal user interaction during automated steps, and the fact that the smaller volumes are less exposed to environmental contaminants than larger volumes which would need to be exposed to open air during mixing. Ruan et al. observed minimal contamination from exogenous nonhuman DNA and no cross-contamination between samples while using their DMF-based digital whole genome sequencing system.
Women who became pregnant within approximately six months of the final dose showed vaccine efficacy estimates between 57% and 86% against parasitaemia in pregnancy. Because malaria and HIV infections frequently overlap geographically, PfSPZ Vaccine has been studied in HIV-positive adults. A randomized, double-blind, placebo-controlled trial in Tanzania administered five intravenous doses to HIV-negative and well-controlled HIV-positive participants. The vaccine was safe in both groups, but protection against CHMI was observed only in HIV-negative individuals, with an estimated vaccine efficacy of 80% in HIV-negative adults and no measurable efficacy in the HIV-positive cohort. Serological profiling indicated that HIV infection did not markedly diminish the magnitude of antibody responses to key sporozoite antigens, although cellular correlates of protection appear impaired in HIV-positive individuals. Recent analyses have examined the immune targets associated with PfSPZ-induced protection. Whole-proteome antibody profiling in Tanzanian trial participants revealed that vaccination elicits a focused IgG and IgM response to a limited set of Plasmodium falciparum antigens, including circumsporozoite protein and several liver- and blood-stage proteins. A whole-genome sieve analysis of parasites obtained from vaccinated and placebo recipients in West African field trials identified distinct parasite polymorphisms associated with vaccine breakthrough infections.
The Times of India noted that these statements highlighted a disconnect between distributor-level performance and theatre-level earnings, suggesting that while certain distributors may have struggled due to high acquisition costs, individual cinemas in multiple territories were able to generate profits from theatrical screenings.
Pennsylvania Department of Health – The company´s objective is to promote healthy behaviors, prevent injury and disease, and assure the safe delivery of quality health care. License: Pursuant of the act of September 26, 1951, P.L., 1539 as amended, a Permit to operate a Clinical Laboratory.
Sources: en.wikipedia.org
==== Aerosol mass spectrometer ==== The Aerodyne AMS provides real-time aerosol mass spectrometry analysis of size-resolved mass concentration of non-refractory components (Ex. organics, sulfate, nitrate, and ammonium). The term non-refractory is assigned to species that evaporate rapidly at 600 °C under vacuum conditions (e.g. organic matter, NH4NO3 and (NH4)2SO4. The schematic of a typical AMS is shown in the figure to the right. The Aerodyne AMS is made up of three sections; The aerosol inlet, the particle sizing chamber, and the particle detection chamber. The aerosol inlet has a flow limiting orifice entrance that is around 100 um in diameter. Once in the chamber the sample goes through aerodynamic focusing lens system, which consist of several orifice lenses that are mount in sequence of decreasing inner diameter. The lens focuses the particles into a narrow particle beam. The beam now travels through the particle sizing chamber, where the particle aerodynamic diameter is measured. The particle sizing chamber is made up of a flight tube maintained at (~ 10−5 torr). The entrance of the flight tube is a mechanical chopper that's used to modulate the particle beam; then using both the fixed length of the tube and the time-resolved detection of the arrival at the end, the particles' velocities can be determined. Using the velocity, the particle's diameter is obtained. As the particle beam exits the flight tube, it enters the particle composition detection chamber. In this section, the particles collide with a heated tungsten element (~600 °C).
== Use and effects == Isoergine occurs naturally in morning glory species, including Ipomoea tricolor (tlitliltzin), Ipomoea corymbosa (ololiuhqui), and Argyreia nervosa (Hawaiian baby woodrose). It has been found to constitute 8 to 35% of total alkaloid content relative to 5 to 58% for ergine. Albert Hofmann, the discoverer of LSD's psychedelic effects, tried 2 mg isoergine orally and experienced feelings of unreality, detachment from the outside world, feelings of mental emptiness, tiredness, and apathy, though no specific sensory distortions were mentioned. He described its effects as similar to those of ergine, which he had tested at doses of up to 2 mg. Subsequently Heim and colleagues assessed ergine at higher doses of 3 to 6 mg orally and observed toxic-like effects, while isoergine at 2 to 5 mg orally produced notable hallucinogenic effects. The psychedelic effects of isoergine observed in this study included some euphoria, synaesthesia, and altered time perception. However, although hallucinogenic, isoergine's effects have been described as not LSD-like. The presence of hallucinogenic effects of isoergine has been described as quite unusual for an isolysergamide derivative. It is thought that ergine and isoergine together may account for most or all of the effects of morning glory seeds, with ergine producing intoxication, sedation, and autonomic side effects and isoergine producing hallucinogenic effects. Conversely, other notable constituents, including elymoclavine, lysergol, and chanoclavine, produced no psychoactive or hallucinogenic effects in humans.
=== Colloquialisms === A large central adiposity deposit has been assigned many common use names, including "spare tire", "love handle", "paunch", "boiler", and "potbelly". Several colloquial terms used to refer to central obesity, and to people who have it, refer to beer drinking. However, there is little scientific evidence that beer drinkers are more prone to central obesity, despite its being known colloquially as "beer belly", "beer gut", or "beer pot". One of the few studies conducted on the subject did not find that beer drinkers are more prone to central obesity than nondrinkers or drinkers of wine or spirits. Chronic alcoholism can lead to cirrhosis, symptoms of which include gynecomastia (enlarged breasts) and ascites (abdominal fluid). These symptoms can suggest the appearance of central obesity.
=== Cationic ERLIC === A negatively charged cation exchange column can be used for ERLIC separations to reduce the influence of anionic (negatively charged) groups on analyte retention. For example, reducing the influence the phosphates of nucleotides or of phosphonyl antibiotic mixtures; or sialic acid groups of modified carbohydrates, to allow separation based more on the basic and/or neutral functional groups of these molecules. Modifying the polarity of a weakly ionic group (e.g. carboxyl) on the surface is easily accomplished by adjusting the pH to be within two pH units of that group's pKa. For strongly ionic functional groups of the surface (i.e. sulfates or phosphates), lower amount of buffer can be used so the residual charge is not completely ion paired. An example of this would be the use of a 12.5mM (rather than the recommended >20mM buffer), pH 9.2 mobile phase on a polymeric, zwitterionic, betaine-sulfonate surface to separate phosphonyl antibiotic mixtures (each containing a phosphate group). This enhances the influence of the column's sulfonic acid functional groups over its surface chemistry, slightly diminished (by pH), quaternary amine. These analytes will show a reduced retention on the column eluting earlier, and in higher amounts of organic solvent, than if a neutral polar HILIC surface were used. This also increases their detection sensitivity by negative ion mass spectrometry.
=== Liquid === Liquid drugs are stored in vials, IV bags, ampoules, cartridges, and prefilled syringes. As with solid formulations, liquid formulations combine the drug product with a variety of compounds to ensure a stable active medication following storage. These include solubilizers, stabilizers, buffers, tonicity modifiers, bulking agents, viscosity enhancers/reducers, surfactants, chelating agents, and adjuvants and also lipid-based carriers. If concentrated by evaporation, the drug may be diluted before administration. For IV administration, the drug may be transferred from a vial to an IV bag and mixed with other materials. For some populations, notably children, where liquid formulation is required but there is no licensed liquid formulation, a modification of an existing solid formulation to create a liquid formulation is sometimes undertaken. There are risks associated with this.
Sources: en.wikipedia.org
2011 Sir Alec John Jeffreys: Developed techniques for DNA fingerprinting and DNA profiling 2010 Pat Brown: Pioneering work in the development of microarrays, and the diverse applications of this technology in genetic research. 2009 Mathias Uhlén 2008 Ruedi Aebersold 2007 Donald F. Hunt 2006 Roger Tsien 2005 Stephen Fodor 2004 Edwin Southern 2003 Franz Hillenkamp and Michael Karas 2002 John Fenn 2001 Csaba Horvath 2000 Leroy Hood 1999 Marvin H. Caruthers for pioneering contributions to the chemical synthesis of DNA and RNA 1998 Bruce Merrifield 1997 Lloyd M. Smith 1996 David Lipman 1995 Klaus Biemann 1994 Frederick Sanger
=== Addiction and withdrawal === Aticaprant was well-tolerated in cocaine use disorder (CUD) patients. A positron emission tomography (PET) study in CUD patients utilizing a KOR selective agonist [11C]GR-103545 radioligand showed CUD individuals with higher KOR availability were more prone to stress-induced relapse. A subsequent PET scan following a three-day cocaine binge showed a decrease in KOR availability, interpreted as increased endogenous dynorphin competing with the radioligand at the KOR binding sites. These findings are in support of the negative affect state and further implicate the KOR/dynorphin system clinically and therapeutically relevant in humans with CUD. Taken together, in drug addiction the KOR system is implicated as a homeostatic mechanism to counteract the acute effects of drugs of abuse. Chronic drug use and stress up-regulate the system in turn leading to a dysregulated state which induces negative affective states and stress reactivity. KOR agonists have also been investigated for their therapeutic potential in the treatment of addiction, particularly substance use disorders. Ibogaine, atypical KOR agonist with G-protein-biased signaling and complex pharmacodynamics involving multiple neurotransmitter systems. Ibogaine's primary active metabolite, noribogaine, acts as a moderate KOR agonist selective for G protein and a potent serotonin reuptake inhibitor. This mechanism, combined with activity at 5-HT2A, 5-HT2C, σ2, and NMDA receptors, likely leads its anti-addictive effects.
== External links == Clinical trial number NCT02782741 for "Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease (COMET)" at ClinicalTrials.gov Clinical trial number NCT01898364 for "Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients" at ClinicalTrials.gov Clinical trial number NCT02032524 for "Avalglucosidase Alfa Extension Study (NEO-EXT)" at ClinicalTrials.gov Clinical trial number NCT03019406 for "A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa (Mini-COMET)" at ClinicalTrials.gov
=== Immunotherapy for cancer === According to Helen Nauts from Cancer Research Institute, on a monograph reviewing the effects of bacterial infections on multiple types of cancer, Ivan Bogdanov, a Bulgarian physician, allegedly produced a vaccine consisting of lactobacillus bulgaricus and used it to treat two patients with myeloma, inducing remission in the two cases, one dying 18 months later due to influenza, and another living 45 months (survival median at the time was about 12–18 months). However, references are internal documents and conversations among hospitals; there's no mention in English medical literature. An article from a commercial site and an alleged documentary are available (in Bulgarian).
Certain countries adopt immigration policies designed to be favourable towards members of diaspora communities with a connection to the country. For example, the Indian government confers Overseas Citizenship of India (OCI) status on foreign citizens of Indian origin to enable them to live and work indefinitely in India. OCI status was introduced in response to demands for dual citizenship by the Indian diaspora, particularly in countries with large populations of Indian origin. It was introduced by The Citizenship (Amendment) Act, 2005 in August 2005. Similar to OCI status, the UK Ancestry visa exempts members of the British diaspora from usual immigration controls. Poland issued the Karta Polaka to citizens of certain northeast European countries with Polish ancestry, but later expanded it to the worldwide Polonia. Some nations recognise a right of return for people with ancestry in that country or a connection to a particular ethnic group. A notable example of this is the right of Sephardi Jews to acquire Spanish nationality by virtue of their community's Spanish origins. Similar exemptions to immigration controls exist for people of Armenian origin seeking to acquire Armenian citizenship. Ghana similarly grants an indefinite right to stay in Ghana to members of the African diaspora, regardless of citizenship. Similarly, Israel maintains a policy permitting members of the Jewish diaspora to immigrate to Israel regardless of prior nationality.
Sources: en.wikipedia.org
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.
No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.
Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.
The lyophilized powder is kept refrigerated at 2 to 8 degrees Celsius and protected from light. Reconstituted solutions should be used promptly. Freezing and thawing repeatedly is avoided.